Pharma News

Pacmilimab by CytomX Therapeutics for Adenocarcinoma: Likelihood of Approval

Pacmilimab is under clinical development by CytomX Therapeutics and currently in Phase II for Adenocarcinoma.

Source link
#Pacmilimab #CytomX #Therapeutics #Adenocarcinoma #Likelihood #Approval

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *